Non-Muscle Invasive Bladder Carcinoma

subtype

Identifier: CI-CAN-00006145
Entity page: /cancer/non-muscle-invasive-bladder-carcinoma ↗
Edges: 125

Neighbours: 16 drugs10 trials
Drawn: 26 of 26 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Non-Muscle Invasive Bladder Carcinoma approved for …APPROVED_FOR7 of 7
← approved for	Pembrolizumabmonoclonal_antibody	supports	FDA ORIG	Non-Muscle Invasive Bladder Carcinoma	1	Regulatory	openfda	graph →
← approved for	Mitomycinsmall_molecule	supports	FDA ORIG

Non-Muscle Invasive Bladder Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 18show all (up to 200)
→ investigated in trials for	Gemcitabinesmall_molecule 14 trials (10 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Mitomycinsmall_molecule 11 trials (7 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Nadofaragene Firadenovecgene_therapy 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Bacillus Calmette-Guerin BCG 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Bicalutamidesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Disitamab Vedotinadc 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal_antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Enfortumab Vedotinadc 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Epirubicinsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Metforminsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →

Non-Muscle Invasive Bladder Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 18show all (up to 200)

→ investigated in trials for

Gemcitabinesmall_molecule

14 trials (10 active) · roll-up of the cancer and its descendants

—

Non-Muscle Invasive Bladder Carcinoma

Observed

Non-Muscle Invasive Bladder Carcinoma studied in …STUDIED_INderived10 of 100show all (up to 200)
→ studied in	NCT06770582Phase 2 · recruiting Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · condition mapped ONTOLOGY_EXACT · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06833073Phase 2 · recruiting A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) · condition mapped ALIAS · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06919965Phase 3 · recruiting A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer · condition mapped ALIAS · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05316155Phase 1/Phase 2 · active not recruiting Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer · condition mapped ALIAS · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06211764Phase 3 · active not recruiting A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) · condition mapped ALIAS · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06319820Phase 3 · recruiting A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer · condition mapped ALIAS · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06877676approved for marketing Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use · condition mapped ALIAS · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07309445recruiting A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States · condition mapped ALIAS · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07800507Phase 1/Phase 2 · not yet recruiting Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer · condition mapped ALIAS · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07804056Phase 3 · recruiting A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer · condition mapped ALIAS · 100 trials mapped (63 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains